Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 5.14 USD 3.21%
Market Cap: 285.7m USD
Have any thoughts about
Foghorn Therapeutics Inc.?
Write Note

Foghorn Therapeutics Inc.
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Foghorn Therapeutics Inc.
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Cash from Operating Activities
-$118.1m
CAGR 3-Years
-56%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Foghorn Therapeutics Inc.
Glance View

Market Cap
285.7m USD
Industry
Biotechnology

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

FHTX Intrinsic Value
6.13 USD
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Foghorn Therapeutics Inc.'s Cash from Operating Activities?
Cash from Operating Activities
-118.1m USD

Based on the financial report for Dec 31, 2023, Foghorn Therapeutics Inc.'s Cash from Operating Activities amounts to -118.1m USD.

What is Foghorn Therapeutics Inc.'s Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-39%

The average annual Cash from Operating Activities growth rates for Foghorn Therapeutics Inc. have been -56% over the past three years , -39% over the past five years .

Back to Top